am not sure why a near-doubling of sales is treated with derision?
are they going broke?
are retailers dumping the product or refusing to stock it?
do we have no-name distributors or retailers?
are we cashflow negative to the extent that we will never see a cashflow positive outcome?
is there no growth potential?
The real nub of the complaints seem to relate to:
1. the speed of sales growth
2. the compensation levels of the top execs?
positive cashflow generation is a product of sales growth. slower sales growth leads to slower point in positive cash flow. But sales are near doubling, plenty of new revenue growth initiatives in pipeline, so revenue growth will come --- just a bit slower.
equally, the remuneration issue always comes as a result of a poorly performing SP ! And it is always the issue that retail shareholders focus on, simply because it is a number that we can easily relate to.
the issue re Exec Chairman's remuneration can be solved by Exec Chairman becoming non-exec, and handing all those responsibilities to CEO. Then we do not lose the marketing ability of Exec Chairman.
YOW is still a growth business imho.
Just ask CEM
cheers
- Forums
- ASX - By Stock
- YOW
- Ann: Yowie Updates YoY Net Sales
Ann: Yowie Updates YoY Net Sales, page-14
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add YOW (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.734M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
YOW (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
SPONSORED BY The Market Online